Daiichinkyo CoDSNKY +4.32%73 PEG Ratio is 0.64 as of Jul. 07, 2026, which is 94% below its 10-year median of 10.78. GuruFocus rates DSNKY with a GF Score™ of 73/100 and a GF Value™ of $37.93 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 349 Drug Manufacturers companies, Daiichinkyo Co ranks better than 80.52% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Daiichinkyo Co's PEG Ratio or its related term are showing as below:
DSNKY'
s PEG Ratio Range Over the Past 10 Years
Min: 0.51 Med: 10.78 Max: 147.66
Current: 0.68
During the past 13 years, Daiichinkyo Co's highest PEG Ratio was 147.66. The lowest was 0.51. And the median was 10.78.
DSNKY's PEG Ratio is ranked better than 80.52% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.7
vs DSNKY: 0.68
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Daiichinkyo Co (OTCPK:DSNKY) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Daiichinkyo Co PEG Ratio Related Terms
Daiichinkyo Co PEG Ratio Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Daiichinkyo Co (DSNKY) has a PEG Ratio of 0.64 as of Jul. 07, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Daiichinkyo Co and its competitors. This is 94% below median its historical median of 10.78. Over the past decade, Daiichinkyo Co's PEG Ratio has ranged from 0.51 to 147.66. According to the industry distribution chart, Daiichinkyo Co ranks #68 out of 349 companies in the Drug Manufacturers industry, placing it in the top 19.5%.
Is Daiichinkyo Co's PEG Ratio too high?
Daiichinkyo Co's current PEG Ratio of 0.64 is 94% below median its 10-year median of 10.78. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 147.66. The Drug Manufacturers industry median PEG Ratio is 1.70. Daiichinkyo Co's value of 0.64 is 62.4% below this industry median. Based on the distribution chart, Daiichinkyo Co ranks #68 out of 349 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Daiichinkyo Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's PEG Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #68 out of 349 companies for PEG Ratio. This places Daiichinkyo Co in the top 20% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.70. Daiichinkyo Co's value of 0.64 is 62.4% below this benchmark. Historically, Daiichinkyo Co's own PEG Ratio has ranged from 0.51 to 147.66 over the past decade. While the company's 10-year median is 10.78 vs. the industry median of 1.70, Daiichinkyo Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current PEG Ratio of 0.64 is 62.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current PEG Ratio is 0.64, which is 94% below median its own 10-year median of 10.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSNKY) is currently considered Significantly Undervalued. The stock's GF Value™ is $37.93, compared to a current price of $17.16 — trading 54.8% below its estimated fair value. The current PEG Ratio is 0.64, which is 94% below median its 10-year median of 10.78 and 62.4% below the Drug Manufacturers industry median of 1.70. Daiichinkyo Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Daiichinkyo Co (DSNKY), the current PEG Ratio is 0.64 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSNKY) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $17.16 is trading 54.8% below its estimated GF Value™ of $37.93.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSNKY:
PEG Ratio: 0.64 (94% below median its 10-year median of 10.78)
GF Value™: $37.93 vs. price of $17.16 (54.8% below fair value)
Industry Position: 62.4% below the Drug Manufacturers median (#68 of 349)
No single metric tells the full story. See the DSNKY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
73GF Score
Get the complete analysis for DSNKY
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSNKY has been successfully added to your 
